Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7063737 | 0.92 | KLKB1 (0.39) | S1PR3 | |
| SCHEMBL6477346 | 0.87 | CES2 (0.36) | P2RX7ALDH1A1CES2 | |
| SCHEMBL6477071 | 0.81 | PTGER4 (0.38) | PTGER4S1PR3P2RX7HTTMAPT | |
| SCHEMBL6484455 | 0.81 | PTGER4 (0.38) | PTGER4S1PR3P2RX7HTTMAPT | |
| SCHEMBL6484735 | 0.76 | CES2 (0.35) | P2RX7CES2 | |
| SCHEMBL6477069 | 0.76 | S1PR3 (0.39) | PTGER4S1PR3P2RX7HTTALDH1A1 | |
| SCHEMBL6818974 | 0.76 | S1PR3 (0.35) | PTGER4S1PR3HTTPPARG | |
| SCHEMBL6289363 | 0.73 | KDM4E (0.43) | PTGER4S1PR3ALDH1A1 | |
| SCHEMBL6292748 | 0.73 | MAOB (0.43) | PTGER4S1PR3SCDMAPTALDH1A1 | |
| SCHEMBL6292798 | 0.73 | PTGER4 (0.40) | PTGER4S1PR3ALDH1A1CACNA1GCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897223-B2 | Pyridine fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-05-24 | — | — | US | claimed |
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | claimed |
| WO-2004014908-A1 | HETEROBICYLCIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-6897223-B2 | Pyridine fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040063673-A1 | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors | JOHNSON ADAM RICHARD (US) | 2004-04-01 | — | — | US | disclosed |
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014384-A2 | CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014908-A1 | HETEROBICYLCIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014908-A1 | HETEROBICYLCIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063673-A1 | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors | MMP13, MMP1, MMP11 | PTGER4 1448/4885S1PR3 304/4885P2RX7 4572/4885 |
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | PTGER4 889/4885S1PR3 2042/4885P2RX7 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.